PhaseBio Pharmaceuticals, Inc. Share Price
Equities
PHAS.Q
US7172241090
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
Sales 2020 | 0.32 25.62 | Sales 2021 | 10.83 867.05 | Capitalization | 126M 10.05B |
---|---|---|---|---|---|
Net income 2020 | -98M -7.85B | Net income 2021 | -131M -10.49B | EV / Sales 2020 | 266,368,150 x |
Net cash position 2020 | 13.43M 1.07B | Net cash position 2021 | 32.69M 2.62B | EV / Sales 2021 | 8,570,663 x |
P/E ratio 2020 |
-0.99
x | P/E ratio 2021 |
-0.87
x | Employees | 60 |
Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 99.76% |
3 months | -99.00% | ||
6 months | -99.50% |
Managers | Title | Age | Since |
---|---|---|---|
Jonathan Mow
CEO | Chief Executive Officer | 59 | 03/12/12 |
Lawrence Perkins
DFI | Director of Finance/CFO | 47 | 30/09/22 |
John Lee
CTO | Chief Tech/Sci/R&D Officer | 56 | 17/04/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edmund Harrigan
BRD | Director/Board Member | 71 | 12/12/18 |
Jonathan Mow
CEO | Chief Executive Officer | 59 | 03/12/12 |
Director/Board Member | 57 | 13/09/21 |
1st Jan change | Capi. | |
---|---|---|
0.00% | 49 | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PHAS.Q Stock